Last reviewed · How we verify

Insulin Detemir, Insulin Insulatard

Rigshospitalet, Denmark · FDA-approved active Small molecule Quality 2/100

Insulin Detemir, Insulin Insulatard is a Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved.

At a glance

Generic nameInsulin Detemir, Insulin Insulatard
SponsorRigshospitalet, Denmark
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Insulin Detemir, Insulin Insulatard

What is Insulin Detemir, Insulin Insulatard?

Insulin Detemir, Insulin Insulatard is a Small molecule drug developed by Rigshospitalet, Denmark.

Who makes Insulin Detemir, Insulin Insulatard?

Insulin Detemir, Insulin Insulatard is developed and marketed by Rigshospitalet, Denmark (see full Rigshospitalet, Denmark pipeline at /company/rigshospitalet-denmark).

What development phase is Insulin Detemir, Insulin Insulatard in?

Insulin Detemir, Insulin Insulatard is FDA-approved (marketed).

Related